Free Trial
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Eliem Therapeutics logo
$1.18 -0.02 (-1.67%)
As of 05/23/2025

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Key Stats

Today's Range
$1.17
$1.23
50-Day Range
$1.13
$1.36
52-Week Range
$2.35
$11.55
Volume
178,602 shs
Average Volume
486,688 shs
Market Capitalization
$35.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Headlines

ELYM Stock Analysis - Frequently Asked Questions

Eliem Therapeutics' stock was trading at $1.80 on January 1st, 2025. Since then, ELYM stock has decreased by 34.4% and is now trading at $1.18.
View the best growth stocks for 2025 here
.

Eliem Therapeutics, Inc. (NASDAQ:ELYM) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19.

Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/08/2021
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.30

Miscellaneous

Free Float
28,354,000
Market Cap
$35.11 million
Optionable
Not Optionable
Beta
-0.39
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ELYM) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners